NCT06989112: DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- State
- Under way
- Phase
- Phase 3
- People
- 600 planned
- Started
- 27 Mar 2025
- Primary completion
- 19 Jan 2029
- Arms
- Arm B: T-DXd + Pembrolizumab
- Results
- None posted
- 27 Mar 2025: Trial started
- 25 May 2025: Trial registered